HomeNDC LookupRxCUI directory › RxCUI 2644440

Nadofaragene firadenovec-vncg 15000000000 VIRAL-PARTICLES/ML Intravesical Suspension — RxCUI 2644440

RxNorm drug concept · Semantic clinical drug
RxCUI 2644440 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2644440
Official nameNadofaragene firadenovec-vncg 15000000000 VIRAL-PARTICLES/ML Intravesical Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES per 20 ML Intravesical Suspension; nadofaragene firadenovec-vncg 300000000000 VIRAL-PARTICLES in 20 ML Intravesical Suspension
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Nadofaragene firadenovec-vncg 15000000000 VIRAL-... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nadofaragene firadenovec-vncg 15000000000 VIRAL-PARTICLES/ML Intravesical Suspension RxCUI 2644440

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Nadofaragene firadenovec 2644436
    • Nadofaragene firadenovec-vncg 2644435
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Adstiladrin 2644441
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nadofaragene firadenovec Intravesical Suspension 2719361
    • Nadofaragene firadenovec-vncg Intravesical Suspension 2719363
    • Nadofaragene firadenovec Intravesical Product 2719360
    • Nadofaragene firadenovec-vncg Intravesical Product 2719362
    • Nadofaragene firadenovec Intravesical Suspension [Adstiladrin] 2719366
    • Nadofaragene firadenovec-vncg Intravesical Suspension [Adstiladrin] 2719367
    • Adstiladrin Intravesical Product 2719365
    • Intravesical Suspension 2719933
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nadofaragene firadenovec-vncg 15000000000 VIRAL-PARTICLES/ML SCDC · 2644437
  • Nadofaragene firadenovec Intravesical Suspension SCDF · 2719361
  • Nadofaragene firadenovec-vncg Intravesical Suspension SCDFP · 2719363
  • Nadofaragene firadenovec Intravesical Product SCDG · 2719360
  • Nadofaragene firadenovec-vncg Intravesical Product SCDGP · 2719362

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2644440 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55566-1050-01 4 VIAL in 1 CARTON (55566-1050-1) / 20 mL in 1 VIAL (55566-... ADSTILADRIN Ferring Pharmaceuticals Inc. 2023-09-05
55566-1050-02 20 mL in 1 VIAL (55566-1050-2) ADSTILADRIN Ferring Pharmaceuticals Inc. 2025-10-13
Observed labelers: Ferring Pharmaceuticals Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9029 Instill adstiladrin, tx dose 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.